Non-small Cell Lung Carcinoma: An Overview on Targeted Therapy

ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)

Volume 16, 14 Issues, 2015

Download PDF Flyer

Current Drug Targets

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 77th of 254 in Pharmacology & Pharmacy

Submit Abstracts Online Submit Manuscripts Online

Francis J. Castellino
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.021
5 - Year: 3.260

Non-small Cell Lung Carcinoma: An Overview on Targeted Therapy

Current Drug Targets, Volume 15 (E-pub ahead of print)

Author(s): Ana Vanessa Nascimento, Hassan Bousbaa, Domingos Ferreira and Bruno Sarmento.

Affiliation: INEB - Instituto de Engenharia Biomédica, Universidade do Porto Rua do Campo Alegre, 823 - 4150-180 Porto, Portugal


Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, most cases are on an advanced and inoperable stage, with limited therapeutic options. Existing therapies have shown to be insufficient and novel strategies are urgently necessary. New advances in understanding the disease at cellular and molecular level however have helped researchers in devising novel strategies for therapy. These directed therapies limit cancer growth by targeting specific molecules related with tumor progression. Such strategies have shown to be more effective than chemotherapy and radiotherapy and can be complemented to existing therapeutic paradigm in augmenting beneficial outcome. Lung cancer could benefit from such innovative therapy. RNA interference (RNAi) is a sequence-specific gene silencing mechanism and, since its discovery widespread applications have pointed it as a powerful tool in cancer treatment. Several on-going clinical trials have been successfully demonstrating its potential as a novel therapeutic, including in the treatment of NSCLC. Here, we revise the recent findings concerning the therapeutic effects of molecular variations associated with NSCLC and where targeted therapies stand in its treatment, with special focus on RNAi-mediated gene silencing as a powerful strategy for NSCLC treatment

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 15
First Page: 1
Page Count: 1
DOI: 10.2174/1389450115666140528151649

Related Journals

Webmaster Contact: Copyright © 2015 Bentham Science